MedTrace Logo

A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants.

NCT07016464 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-02-04

No results posted yet for this study

Summary

This study is testing if the medicine REM0045392 is safe and well-tolerated. It also looks at whether food affects how the medicine works.

The medicine will be tested in Healthy men (Part 1 and 2) and Healthy Older men and women (Part 3).

Participants will take the medicine once (in Part 1) or during 14 days (in Part 2 and 3), with increasing doses.

REM0045392 is being developed as a treatment for Alzheimer's disease.

Conditions

  • Healthy

Interventions

DRUG

REM0045392

Liquid formulation

DRUG

Placebo

Liquid formulation

Sponsors & Collaborators

  • reMYND

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2025-06-23
Completion
2025-06-23

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07016464 on ClinicalTrials.gov